Who are Marevan®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sodium warfarin, generic warfarin #2, low intensity warfarin, Warfarin Sodium Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/marevan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Marevan® — Competitive Intelligence Brief

Marevan® (Marevan®) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist (coumarin anticoagulant). Area: Cardiovascular.

marketed Vitamin K antagonist (coumarin anticoagulant) Vitamin K epoxide reductase complex 1 (VKORC1) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Marevan® (Marevan®) — Federal University of São Paulo. Marevan is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors, thereby reducing blood coagulation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Marevan® TARGET	Marevan®	Federal University of São Paulo	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
generic warfarin #2	generic warfarin #2	Federal University of São Paulo	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
low intensity warfarin	low intensity warfarin	The First Affiliated Hospital with Nanjing Medical University	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin Sodium Tablets	Warfarin Sodium Tablets	Guangdong Raynovent Biotech Co., Ltd	phase 3	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist (coumarin anticoagulant) class)

Federal University of São Paulo · 2 drugs in this class
Guangdong Raynovent Biotech Co., Ltd · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
University of Padova · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Marevan® — Competitive Intelligence Brief. https://druglandscape.com/ci/marevan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab